Contraception during the perimenopause

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Although the absolute risk of pregnancy is lower during the perimenopause due to decreased fertility and decreased coital frequency, unintended pregnancy occurs at ratios similar to those observed in young women, and pregnancies that do occur are at high risk for maternal complications and poor outcomes such as miscarriage or chromosomal abnormalities. Therefore all premenopausal women should receive counselling that includes discussion of sexual habits and contraception during routine health care encounters. The majority of US women in this age group use permanent contraception, but other methods can be safe and effective and can have non-contraceptive benefits. No contraceptive method is contraindicated based on age alone. However, estrogen-containing methods should be reserved for women without cardiovascular or thrombotic risk factors. The levonorgestrel intrauterine system (LNG-IUS, Mirena®) has particular benefits during perimenopause and is safe for use in nearly all women. The LNG-IUS is approved for treatment of heavy menstrual bleeding, a common concern during the perimenopause. A substantial literature supports the use of the LNG-IUS for endometrial protection during transition from contraception to hormone therapy, although this is off-label in the United States. Reliable contraception should be used until menopause is confirmed either by cessation of menses for 2 years prior to age 50, for 1 year after age 50, or by two elevated follicle-stimulating hormone (FSH) values ≥20-30 IU/l while off hormonal methods for at least 2 weeks. Sterility cannot be assumed until at least age 60 because spontaneous pregnancies have been reported in women up to age 59.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalMaturitas
Volume76
Issue number3
DOIs
StatePublished - Nov 2013

Fingerprint

Perimenopause
Liquefied natural gas
Contraception
Levonorgestrel
Pregnancy
Follicle Stimulating Hormone
Contraceptive Agents
Health care
Labels
Estrogens
Hormones
Menstruation
Coitus
Spontaneous Abortion
Menopause
Chromosome Aberrations
Infertility
Habits
Fertility
Counseling

Keywords

  • Contraception
  • Endometrial protection
  • Heavy menstrual bleeding
  • Older reproductive
  • Perimenopause

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Contraception during the perimenopause. / Baldwin, Maureen; Jensen, Jeffrey.

In: Maturitas, Vol. 76, No. 3, 11.2013, p. 235-242.

Research output: Contribution to journalArticle

@article{febfbd3ac94647bab3b4bf0a08cc491b,
title = "Contraception during the perimenopause",
abstract = "Although the absolute risk of pregnancy is lower during the perimenopause due to decreased fertility and decreased coital frequency, unintended pregnancy occurs at ratios similar to those observed in young women, and pregnancies that do occur are at high risk for maternal complications and poor outcomes such as miscarriage or chromosomal abnormalities. Therefore all premenopausal women should receive counselling that includes discussion of sexual habits and contraception during routine health care encounters. The majority of US women in this age group use permanent contraception, but other methods can be safe and effective and can have non-contraceptive benefits. No contraceptive method is contraindicated based on age alone. However, estrogen-containing methods should be reserved for women without cardiovascular or thrombotic risk factors. The levonorgestrel intrauterine system (LNG-IUS, Mirena{\circledR}) has particular benefits during perimenopause and is safe for use in nearly all women. The LNG-IUS is approved for treatment of heavy menstrual bleeding, a common concern during the perimenopause. A substantial literature supports the use of the LNG-IUS for endometrial protection during transition from contraception to hormone therapy, although this is off-label in the United States. Reliable contraception should be used until menopause is confirmed either by cessation of menses for 2 years prior to age 50, for 1 year after age 50, or by two elevated follicle-stimulating hormone (FSH) values ≥20-30 IU/l while off hormonal methods for at least 2 weeks. Sterility cannot be assumed until at least age 60 because spontaneous pregnancies have been reported in women up to age 59.",
keywords = "Contraception, Endometrial protection, Heavy menstrual bleeding, Older reproductive, Perimenopause",
author = "Maureen Baldwin and Jeffrey Jensen",
year = "2013",
month = "11",
doi = "10.1016/j.maturitas.2013.07.009",
language = "English (US)",
volume = "76",
pages = "235--242",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Contraception during the perimenopause

AU - Baldwin, Maureen

AU - Jensen, Jeffrey

PY - 2013/11

Y1 - 2013/11

N2 - Although the absolute risk of pregnancy is lower during the perimenopause due to decreased fertility and decreased coital frequency, unintended pregnancy occurs at ratios similar to those observed in young women, and pregnancies that do occur are at high risk for maternal complications and poor outcomes such as miscarriage or chromosomal abnormalities. Therefore all premenopausal women should receive counselling that includes discussion of sexual habits and contraception during routine health care encounters. The majority of US women in this age group use permanent contraception, but other methods can be safe and effective and can have non-contraceptive benefits. No contraceptive method is contraindicated based on age alone. However, estrogen-containing methods should be reserved for women without cardiovascular or thrombotic risk factors. The levonorgestrel intrauterine system (LNG-IUS, Mirena®) has particular benefits during perimenopause and is safe for use in nearly all women. The LNG-IUS is approved for treatment of heavy menstrual bleeding, a common concern during the perimenopause. A substantial literature supports the use of the LNG-IUS for endometrial protection during transition from contraception to hormone therapy, although this is off-label in the United States. Reliable contraception should be used until menopause is confirmed either by cessation of menses for 2 years prior to age 50, for 1 year after age 50, or by two elevated follicle-stimulating hormone (FSH) values ≥20-30 IU/l while off hormonal methods for at least 2 weeks. Sterility cannot be assumed until at least age 60 because spontaneous pregnancies have been reported in women up to age 59.

AB - Although the absolute risk of pregnancy is lower during the perimenopause due to decreased fertility and decreased coital frequency, unintended pregnancy occurs at ratios similar to those observed in young women, and pregnancies that do occur are at high risk for maternal complications and poor outcomes such as miscarriage or chromosomal abnormalities. Therefore all premenopausal women should receive counselling that includes discussion of sexual habits and contraception during routine health care encounters. The majority of US women in this age group use permanent contraception, but other methods can be safe and effective and can have non-contraceptive benefits. No contraceptive method is contraindicated based on age alone. However, estrogen-containing methods should be reserved for women without cardiovascular or thrombotic risk factors. The levonorgestrel intrauterine system (LNG-IUS, Mirena®) has particular benefits during perimenopause and is safe for use in nearly all women. The LNG-IUS is approved for treatment of heavy menstrual bleeding, a common concern during the perimenopause. A substantial literature supports the use of the LNG-IUS for endometrial protection during transition from contraception to hormone therapy, although this is off-label in the United States. Reliable contraception should be used until menopause is confirmed either by cessation of menses for 2 years prior to age 50, for 1 year after age 50, or by two elevated follicle-stimulating hormone (FSH) values ≥20-30 IU/l while off hormonal methods for at least 2 weeks. Sterility cannot be assumed until at least age 60 because spontaneous pregnancies have been reported in women up to age 59.

KW - Contraception

KW - Endometrial protection

KW - Heavy menstrual bleeding

KW - Older reproductive

KW - Perimenopause

UR - http://www.scopus.com/inward/record.url?scp=84887416535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887416535&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2013.07.009

DO - 10.1016/j.maturitas.2013.07.009

M3 - Article

C2 - 23932427

AN - SCOPUS:84887416535

VL - 76

SP - 235

EP - 242

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 3

ER -